Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study

Paul Emery,Gerd R Burmester,Vivian P Bykerk,Bernard G Combe,Daniel E Furst,Michael A Maldonado,Tom Wj Huizinga

doi:10.1136/rmdopen-2018-000840

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study

Paul Emery, Gerd R Burmester + Show 5 more

Open Access

https://doi.org/10.1136/rmdopen-2018-000840

Copy DOI

Journal: RMD Open	Publication Date: Feb 1, 2019
Citations: 9	License type: open-access

Affiliation: University of Leeds, Leeds Teaching Hospitals NHS Trust, NIHR Leeds Musculoskeletal Biomedical Research Unit, Charité - Universitätsmedizin Berlin, Hospital for Special Surgery, University of Montpellier, University Hospital of Montpellier, University of California, Los Angeles, Bristol-Myers Squibb (United States), Leiden University Medical Center

#Health Assessment Questionnaire Disability Index Scores #Treatment Withdrawal In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesTo complete reporting of outcomes after total withdrawal of all rheumatoid arthritis (RA) therapy and re-treatment after flare in Assessing Very Early Rheumatoid arthritis Treatment study (NCT01142726).MethodsPatients with early RA...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: RMD Open

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.